- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03521973
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in 1-12 Year-old Gabonese Children Naturally Exposed to Malaria Parasites
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The trial will be performed in 200 healthy Gabonese children, recruited across three age-strata: 7-12, 3-6 and 1-2 years (12-35 months). Within each age-stratum, volunteers will be randomized in a 2:1 ratio to receive three doses via direct venous inoculation (DVI) of either PfSPZ Vaccine (0.9x10^6) or normal saline (NS) on days 0, 7 and 28 respectively; a minimum of 40 and a maximum of 100 volunteers are included in each of these age-strata.
In total, approximately 133 children will receive PfSPZ Vaccine and approximately 67 children will receive placebo. Randomization will be stratified by age-stratum, using permuted blocks of randomized size (3, 6, or 9). The start of inclusion into each age-stratum will be staggered, such that immunization of the first 3-6-year-olds will not commence until two weeks after start of immunization in the first 7-12-year-olds, and immunizations in the first 1-2-year-olds will not commence until two weeks after start of immunization in the first 3-6-year-olds. All volunteers will receive presumptive treatment with artemether-lumefantrine two weeks prior to final immunization (day 14). All volunteers will receive presumptive treatment with age-standardized 3-day course of oral artemether-lumefantrine (AL) ~two weeks prior to first immunization and again two weeks prior to final immunization.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Moyen-Ogooué
-
Lambaréné, Moyen-Ogooué, Gabon
- Centre de Recherches Médicales de Lambaréné (CERMEL)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy children aged 1 to 12 years
- Provision of written informed consent of a legal representative of age 18 or above and provision of informed assent by participants in concordance with Gabonese national guidelines.
- Able and willing to comply with all study requirements
- Residence in the area throughout the study period
- Household member reachable by mobile phone during the immunization phase
Exclusion Criteria:
- Receipt of an investigational product in the 30 days preceding enrollment
- Prior receipt of a malaria vaccine
- Immunization with more than 3 other vaccines or at least on elive vaccine within the past four weeks
- Use of immunoglobulins or blood products within 3 months prior to immunization with the investigational product
- Known or suspected HIV infection or any other immunosuppressive state
- Positive for hepatitis B surface antigen (HBs-antigen)
- Seropositive for hepatitis C virus (antibodies to HCV)
- A hemoglobin concentration <9 g/dl (applies at enrollment only)
- History of non-febrile or atypical febrile seizures
- Pregnancy or lactation
- Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the child because of participation in the study or impair interpretation of the study data
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1- PfSPZ-Vaccine
Children aged 7-12 years (inclusive) of age will be enrolled in this group. N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals. |
Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
|
Placebo Comparator: Group 2
Children aged 7-12 years (inclusive) of age will be enrolled in this group. N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals. |
0.9% Sodium chloride
Other Names:
|
Experimental: Group 3
Children aged 3-6 years (inclusive) of age will be enrolled in this group. N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1. |
Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
|
Placebo Comparator: Group 4
Children aged 3-6 years (inclusive) of age will be enrolled in this group. N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2. |
0.9% Sodium chloride
Other Names:
|
Experimental: Group 5
Children aged 1-2 years (inclusive) of age will be enrolled in this group. N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3. |
Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
|
Placebo Comparator: Group 6
Children aged 1-2 years (inclusive) of age will be enrolled in this group. N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4. |
0.9% Sodium chloride
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of volunteers who become parasitemic will be recorded, detected by Thick Blood Smear (TBS) microscopy
Time Frame: From 2 weeks to 6 months after the third PfSPZ Vaccine immunization
|
Time to event and proportional analysis of episodes of P. falciparum parasitemia, detected actively or passively by TBS microscopy.
Vaccine efficacy will be measured in the mITT population.
|
From 2 weeks to 6 months after the third PfSPZ Vaccine immunization
|
Proportion of volunteers who become parasitemic with temperature ≥37.5°C or history of fever
Time Frame: From 2 weeks to 6 months after the third PfSPZ Vaccine immunization
|
Time to event and proportional analysis of episodes of P. falciparum parasitemia with temperature ≥37.5°C or history of fever within the last 24 hours (P.
falciparum malaria with clinical manifestations).
Vaccine efficacy against P. falciparum malaria with clinical manifestations will be measured in the mITT population using hierarchical testing; the secondary will only be tested when the primary endpoint shows a significant difference.
|
From 2 weeks to 6 months after the third PfSPZ Vaccine immunization
|
The occurrence and frequency of adverse events (AEs)
Time Frame: From the time of each PfSPZ Vaccine immunization until 7 days after each dose
|
The occurrence and frequency of Grade 3 solicited adverse AEs (related or unrelated) after vaccination
|
From the time of each PfSPZ Vaccine immunization until 7 days after each dose
|
The occurrence and frequency of AEs
Time Frame: From the time of first PfSPZ Vaccine immunization until 28 days after the last dose
|
The occurrence and frequency of Grade 3 unsolicited adverse AEs (related or unrelated) after vaccination
|
From the time of first PfSPZ Vaccine immunization until 28 days after the last dose
|
The occurrence and frequency of serious adverse events (SAEs)
Time Frame: Around 27 months (from day of first immunization through study completion)
|
The occurrence and frequency of SAEs (related or unrelated) after vaccination
|
Around 27 months (from day of first immunization through study completion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The occurrence of all related solicited AE
Time Frame: From the time of each PfSPZ Vaccine immunization until 7 days after each dose
|
The occurrence of all related solicited AE after vaccination
|
From the time of each PfSPZ Vaccine immunization until 7 days after each dose
|
The occurrence of all related unsolicited AEs
Time Frame: From the time of first PfSPZ Vaccine immunization until 28 days after the last dose
|
The occurrence of all related unsolicited AE after vaccination
|
From the time of first PfSPZ Vaccine immunization until 28 days after the last dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Selidji Agnandji, MD, Centre de Recherches Médicales de Lambaréné (CERMEL)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LaSPZV1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Normal Saline
-
Texas Cardiac Arrhythmia Research FoundationSuspendedVentricular ArrythmiaUnited States
-
The Catholic University of KoreaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Texas Cardiac Arrhythmia Research FoundationCompleted
-
MemorialCare Health SystemCompletedLength of Labor | Second Stage of Labor | Intravenous Hydration of LaborUnited States
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
University of MichiganRadiological Society of North AmericaTerminated
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia